Antibody Conjugated Polymeric Prodrugs the Future for Cancer Therapy
| Dublin Core | PKP Metadata Items | Metadata for this Document | |
| 1. | Title | Title of document | Antibody Conjugated Polymeric Prodrugs the Future for Cancer Therapy |
| 2. | Creator | Author's name, affiliation, country | Joseph Asamoah-Asare; Hepatobiliary and Enteric Research Center, Xiangya Hospital, Changsha, Hunan; China |
| 2. | Creator | Author's name, affiliation, country | Yangde Zhang; Hepatobiliary and Enteric Research Center, Xiangya Hospital, Changsha, Hunan; China |
| 2. | Creator | Author's name, affiliation, country | Yuxiang Chen; Hepatobiliary and Enteric Research Center, Xiangya Hospital, Changsha, Hunan; China |
| 3. | Subject | Discipline(s) | Biomedical Engineering; Drug Delivery System |
| 3. | Subject | Keyword(s) | Cancer; Cancer Therapy; Drug Delivery; Targeted Therapy; Antibody Conjugated Polymeric Prodrugs; Nanoparticles |
| 4. | Description | Abstract |
Cancer is one of the most devastating conditions affecting humans. Current drugs used in the treatment of cancers and other diseases are becoming ineffective as a result of drug resistance, occurring naturally as well as the abuse and misuse of drugs as well as issues of patient compliance to therapy due to its high toxicity. To overcome this resistance and improve the efficacy of these drugs, a selective drug delivery is essential. Such selective or targeted delivery is the use of antibody conjugated polymeric drugs in the treatment of cancers. A targeted delivery of cytotoxic agents to tumors is believed to improve both their anti-tumor effect and safety. This review focuses on the recent cancer drug therapy such as chemotherapy, immunotherapy, hormone therapy and antibody drug conjugates as well as research on new therapies such as polymer drug conjugates and antibody conjugated polymeric prodrugs. Challenges encountered in antibody conjugated polymeric prodrugs for cancer treatment and measures to improve it such as nanosizing the delivery systems are also discussed. |
| 5. | Publisher | Organizing agency, location | |
| 6. | Contributor | Sponsor(s) | National Hi-tech Project |
| 7. | Date | (YYYY-MM-DD) | 2013-11-21 |
| 8. | Type | Status & genre | Peer-reviewed Article |
| 8. | Type | Type | |
| 9. | Format | File format | |
| 10. | Identifier | Uniform Resource Identifier | http://medical.cloud-journals.com/index.php/IJABB/article/view/Med-114 |
| 11. | Source | Journal/conference title; vol., no. (year) | International Journal of Advanced Biotechnology and Bioengineering; Published Papers |
| 12. | Language | English=en | en |
| 14. | Coverage | Geo-spatial location, chronological period, research sample (gender, age, etc.) | |
| 15. | Rights | Copyright and permissions |
Copyright Terms & Conditions Authors who publish with this journal agree to the following terms: a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work Cloud Publications reserves the right to amend/change the copyright policy; with/without notice. |